Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.143129 http://scihub22266oqcxt.onion/10.1172/jci.insight.143129 33427208!7821590!33427208     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JCI+Insight 2021 ; 6 (1): ä Nephropedia Template TP {{tp|p=33427208|t=2021. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022 |pdf=|usr=}}{{33427208}} gab.com Text Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022 JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33427208 #FOAvip The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coupled with a lack of therapeutics, has paralyzed the globe. Although significant effort has been invested in identifying antibodies that block infection, the ability of antibodies to target infected cells through Fc interactions may be vital to eliminate the virus. To explore the role of Fc activity in SARS-CoV-2 immunity, the functional potential of a cross-SARS-reactive antibody, CR3022, was assessed. CR3022 was able to broadly drive antibody effector functions, providing critical immune clearance at entry and upon egress. Using selectively engineered Fc variants, no protection was observed after administration of WT IgG1 in mice or hamsters. Conversely, the functionally enhanced Fc variant resulted in increased pathology in both the mouse and hamster models, causing weight loss in mice and enhanced viral replication and weight loss in the more susceptible hamster model, highlighting the pathological functions of Fc-enhancing mutations. These data point to the critical need for strategic Fc engineering for the treatment of SARS-CoV-2 infection. Twit Text FOAVip Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022 ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33427208 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33427208 #FOAvip English Wikipedia <ref>{{Cite pmid|33427208}}</ref> Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022 #MMPMID33427208 Atyeo C; Slein MD; Fischinger S; Burke J; Schafer A; Leist SR; Kuzmina NA; Mire C; Honko A; Johnson R; Storm N; Bernett M; Tong P; Zuo T; Lin J; Zuiani A; Linde C; Suscovich T; Wesemann DR; Griffiths A; Desjarlais JR; Juelg BD; Goudsmit J; Bukreyev A; Baric R; Alter G JCI Insight 2021[Jan]; 6 (1): ä PMID33427208show ga The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coupled with a lack of therapeutics, has paralyzed the globe. Although significant effort has been invested in identifying antibodies that block infection, the ability of antibodies to target infected cells through Fc interactions may be vital to eliminate the virus. To explore the role of Fc activity in SARS-CoV-2 immunity, the functional potential of a cross-SARS-reactive antibody, CR3022, was assessed. CR3022 was able to broadly drive antibody effector functions, providing critical immune clearance at entry and upon egress. Using selectively engineered Fc variants, no protection was observed after administration of WT IgG1 in mice or hamsters. Conversely, the functionally enhanced Fc variant resulted in increased pathology in both the mouse and hamster models, causing weight loss in mice and enhanced viral replication and weight loss in the more susceptible hamster model, highlighting the pathological functions of Fc-enhancing mutations. These data point to the critical need for strategic Fc engineering for the treatment of SARS-CoV-2 infection. |Animals[MESH] |Antibodies, Monoclonal[MESH] |Antibodies, Neutralizing/genetics/*pharmacology/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*immunology/physiopathology[MESH] |Cricetinae[MESH] |Cross Reactions[MESH] |Epitopes[MESH] |Humans[MESH] |Immunity, Innate/*drug effects/immunology[MESH] |Immunoglobulin Fc Fragments/*genetics[MESH] |Immunoglobulin G/genetics/*pharmacology/therapeutic use[MESH] |Mesocricetus[MESH] |Mice[MESH] |Middle East Respiratory Syndrome Coronavirus/drug effects/immunology[MESH] |Protein Engineering[MESH] |Receptors, Fc/immunology[MESH] |SARS-CoV-2/*drug effects/immunology[MESH] |Severe acute respiratory syndrome-related coronavirus/drug effects/immunology[MESH] |Severity of Illness Index[MESH] |Spike Glycoprotein, Coronavirus/immunology[MESH] |THP-1 Cells[MESH] |Viral Load/drug effects[MESH] |Virus Replication/*drug effects[MESH]Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-(epmc).pdf DeepDyve Pubget Overpricing